Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

    We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...

    Learn More
    From Chaos to Cohesion

    Coronavirus

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    The COVID-19 pandemic has brought about many long-term changes to the pharma industry. One area that has seen effects directly caused by COVID-19 has been in sales operations design, management, and engagement with customers due to increased access restrictions of sales reps to physicians. COVID-19 has also accelerated institutional rethinking of the level and role of direct sales forces in the ...
    Learn More
    Why The COVID-19 Recession Is Different And More Dangerous Than The Great Recession

    Why The COVID-19 Recession Is Different And More Dangerous Than The Great Recession

    The U.S. and much of the global economy is experiencing the most severe recession since the Great Depression, as witnessed by the dramatic and historic downturn in Q2 2020 U.S. GDP. It would also be justified in saying this is the most unusual recession the U.S. has experienced, and maybe, the most difficult to resolve. Moreover, it is likely the most dangerous recession since the Great ...
    Learn More
    What Analytical Techniques Should Pharma Companies Implement To Estimate And Forecast COVID-19 Effects When Recovery Is Geographically Uneven?

    What Analytical Techniques Should Pharma Companies Implement To Estimate And Forecast COVID-19 Effects When Recovery Is Geographically Uneven?

    Hope for a strong and quick recovery from the COVID-19 induced U.S. recession became more uncertain with the dramatic and historic decline in Q2 2020 U.S. GDP. There are also economic signs that a full economic recovery to pre-pandemic levels is still elusive. Continued economic uncertainty remains. Further, while the resurgence of COVID-19 cases seen in many states this past June, especially in ...
    Learn More
    What Is At Stake For The Pharma Industry From The Upcoming 2020 Elections: How Should Companies Prepare?

    What Is At Stake For The Pharma Industry From The Upcoming 2020 Elections: How Should Companies Prepare?

    The upcoming November 2020 presidential and congressional elections represent a key event for the pharma industry. Current industry focus is on COVID-19, the effects from public policy mandates on pharma business operations, resulting in recessionary effects on market access and affordability, and the search for effective vaccines and treatments. Yet, a Democratic Party election sweep by winning ...
    Learn More
    Will The Pharma Industry’s Response To COVID-19 Positively Affect Its Image? A Commentary

    Will The Pharma Industry’s Response To COVID-19 Positively Affect Its Image? A Commentary

    The pharmaceutical industry has stepped up in a big way in search of vaccines and effective treatments for COVID-19. One reference cited at least 250 drugs and 95 vaccines under investigation related to COVID-19. The coronavirus pandemic has clearly shown the societal value of having a pharmaceutical industry with a robust capability to develop new medicines and to operate in an economic system ...
    Learn More
    Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning

    Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning

    The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...
    Learn More
    COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes

    COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes

    This white paper investigates the research framework to model the expected effects of the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceutical utilization due to the economic effects of a deep and long recession. Four effects caused by a deep recession that will adversely affect the utilization of branded/biologic drugs, which, in turn, will cause a ...
    Learn More
    Coronavirus Pandemic Effects On Incentive Compensation

    Coronavirus Pandemic Effects On Incentive Compensation

    The rapid spread of COVID 19 has resulted in pharma companies facing significant ramifications on their business, requiring a change in assumptions, thinking, and decisions going forward. One such critical area of effect from the pandemic is on incentive compensation (IC). Pharma company investment in the sales force is significant in both personnel and economic terms. Mandates on social ...
    Learn More
    How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?

    How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?

    The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmaceutical industry. The coronavirus pandemic also illustrates the need for companies to have empirical systems in place to act quickly to mitigate the effects of such events when they do occur. This white paper provides a ...
    Learn More